Sell or avoid positions; expect significant price volatility and reduced liquidity as the stock moves to OTC markets. Monitor for any potential reverse split or capital raise attempts to regain listing, but timeline appears closed. The recent March offerings suggest the company had limited options and still failed.
RVPH drugs
RVPH drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 13 $0.3521entry
- T+1 · 6mo ago +10.76%α +9.99% · $0.3900
- T+5 · 6mo ago +15.05%α +16.21% · $0.4051
- T+20 · 5mo ago +115.85%α +116.46% · $0.7600
- T+60 · 3mo ago +35.62%α +31.19% · $0.4775
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Reviva Pharmaceuticals received a final delisting notice from Nasdaq due to failure to maintain the minimum $1.00 bid price. Trading will be suspended on May 14, 2026, and the stock will transition to the OTCQB Venture Market. The delisting severely reduces liquidity and institutional access, compounding distress signaled by recent dilutive offerings.
Key Facts
- Nasdaq Hearings Panel determined to delist common stock due to non-compliance with Bid Price Requirement (Nasdaq Listing Rule 5550(a)(2)).
- Trading on Nasdaq will be suspended as of open of trading on May 14, 2026.
- Common stock will be quoted on OTCQB Venture Market under symbol RVPH starting May 14, 2026.
- Company filed two 424B5 offerings in March 2026 (approximately 55-56 days prior), indicating recent capital raises that failed to regain compliance.
Financial Impact
No specific financial figures provided in the filing; delisting expected to materially impair access to capital and stock liquidity.
Risk Factors
- Further price decline due to loss of institutional investors and index inclusion.
- Penny stock classification and stricter broker requirements may reduce retail participation.
- OTC markets may have limited liquidity, causing wide bid-ask spreads and difficulty exiting positions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-016538 |
| Document: 0001437749-26-016538-index.html | 0001437749-26-016538 |
| Document: 0001437749-26-016538.txt | 0001437749-26-016538 |
Track record
12 reports on RVPH
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +22.98% at T+20 after the Jul 10, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 No price data
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.3533 Now $0.3504 −0.81% settles Feb 11
- Nov 9, 20267d ago DEF 14A Neutral 4/10 Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
- Jul 10, 202618w ago 25-NSE Bearish 7/10 Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
- May 13, 202626w ago Press Release Bearish 7/10 Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
- May 13, 202626w ago 8-K Bearish 8/10 Viewing Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
- Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
- Mar 30, 202633w ago Press Release Mixed 6/10 Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
- Mar 18, 202634w ago Press Release Bearish 6/10 Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers